Iris Acquisition CORP 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
Iris Acquisition Corp's 10-K filing reveals challenges in completing a business combination by June 30, 2025, alongside material weaknesses in internal controls.
10-K: Iris Acquisition Corp Amends Business Combination Agreement, Extends Deadline to July 31, 2024
Iris Acquisition Corp extends the deadline for its business combination with Liminatus Pharma to July 31, 2024, through a third amendment to their agreement.